Unique Experiences with Intercontinental Trials in Stroke - Part II

Supported by the Canadian Medical Research Council we performed a randomized trial extending from Newfoundland to British Columbia. With others a number of observations showed that aspirin will reduce stroke. With National Institute of Neurological Disorders and Stroke support we learned who would b...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of neurological sciences 2013-09, Vol.40 (5), p.645-651
Main Authors: Barnett, H.J.M., Laidlaw, John (Jack) Coleman
Format: Article
Language:English
Subjects:
Aspirin - therapeutic use
Biological and medical sciences
Canada - epidemiology
Fibrinolytic Agents - therapeutic use
Historical Review
Humans
Longitudinal Studies
Medical sciences
Mitral Valve Prolapse - etiology
Mitral Valve Prolapse - therapy
Neurology
Randomized Controlled Trials as Topic
Risk Factors
Stroke - complications
Stroke - therapy
Treatment Outcome
Vascular diseases and vascular malformations of the nervous system
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Supported by the Canadian Medical Research Council we performed a randomized trial extending from Newfoundland to British Columbia. With others a number of observations showed that aspirin will reduce stroke. With National Institute of Neurological Disorders and Stroke support we learned who would benefit and not from surgery in these stroke threatened carotid diseased patients. We evaluated the upper limits of acceptability of complications beyond which harm was done. Amassing this large data base of approximately 5000 individuals, followed for five years, previously unknown carotid phenomena were observed: 1. Ischemic stroke occurs in patients with prolapsing mitral valves; 2. There is risk of stroke in patients with residual thrombi in the occluded stump of the carotid artery; 3. We detected a lower risk than expected in patients with nearly occluded carotid arteries. We support the contention of Yusuf and Cairns' that Canada needs to give more financial support to purely clinical research. It pays off!
ISSN:0317-1671
2057-0155
DOI:10.1017/S0317167100014864